ITPP
None
Technical catalog description
ITPP (myo-inositol trispyrophosphate) is a synthetic allosteric modifier of hemoglobin that right-shifts the oxygen-hemoglobin dissociation curve, causing red blood cells to release more oxygen to tissues at a given partial pressure. In simple terms: it improves oxygen delivery to working muscle without changing red blood cell count.
It has attracted interest in endurance sports as a potential non-EPO oxygen-delivery enhancer. Animal studies showed significant VO₂max and endurance improvements. Human data is limited to early trials, and it is not yet approved or commercially available for performance use, so self-experimenters obtain it as a research chemical.
Read next
ITPP occupies a genuinely interesting mechanistic niche. Most oxygen-delivery enhancement strategies in endurance sports focus on increasing red blood cell mass (EPO, altitude training, blood doping). ITPP proposes a different approach: make existing red blood cells release more oxygen to tissues more readily. This would theoretically improve VO₂max and endurance without the hematocrit-related cardiovascular risks of polycythemia.
The animal data is compelling. The human data is extremely thin. It is not yet possible to say with confidence how well the animal results translate to humans in practice.
Unknown long-term effects in humans, so treat it as experimental
Potential cardiovascular effects from hemoglobin allosteric modification
oxygen saturation and cardiovascular response if monitoring
hemoglobin and hematocrit
Anyone without clear endurance performance goals and risk tolerance for experimental compounds
Self-administered IV use without appropriate preparation and monitoring
ITPP is chosen by endurance-focused users who are looking for oxygen-delivery enhancement without EPO’s legal and health risk profile. The mechanism-first community finds it attractive precisely because it targets a different part of the oxygen transport chain. Cyclists, triathletes, and high-intensity endurance athletes are the primary users in self-experimentation circles.
Self-experimenter reports are sparse and highly variable. Some report noticeable endurance improvements; others report nothing obvious. The practical takeaway is simple: interesting mechanism, uncertain human translation, and a thin evidence base.
Treating animal data as a direct prediction of human response. Self-administering IV without appropriate preparation. Combining it with EPO or other RBC-elevating strategies without understanding the compounded cardiovascular effects.
Compared with EPO, ITPP targets oxygen delivery rather than red blood cell production. That means a different risk profile, a different mechanism, and a much thinner evidence base. Compared with altitude training or NAD+ for endurance support, ITPP is far more experimental and specific in its mechanism.